Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (late spermatids) | 0.10 |
| chemistry Open Targets | compounds already reach it: lebrikizumab, anrukinzumab, cnto-5825 +4 | 0.90 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 39 Parkinson's papers of 18,486 | 0.52 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6057
Sealed predictions
- IL13 in dopamine neurons, braak-0.32 (p 0.402) → -0.12 (p 0.750)receipt 6064
Swarm cases
receipt 6064: IL13 in dopamine neurons, braak
- power
- full sample -0.23 (p 0.355, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.24 (p 0.341, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.40 (p 0.097, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.14, sign flips 0; without severely affected donors -0.23 (p 0.355, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL13 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts